our

Story

Ventrix was founded based on a new approach to tissue engineering, focusing on repairing the microenvironment. We have guided our first product, VentriGel, from concept to the clinic. We have focused on the science behind VentriGel and are passionate about improving the quality of life of cardiovascular disease patients.

 
StockSnap_FXWVRMLUPF.jpg
 

ventrix

Team

 

Adam Kinsey, phd - chief executive officer

Dr. Kinsey has focused on launching and supporting biotechnology startups. Prior to Ventrix, Dr. Kinsey was a consultant in business development and intellectual property strategy at a variety of biotech startups. He was also formerly at Wilson Sonsini Goodrich & Rosati, where he focused on helping fledgling companies and venture capital investors establish and identify IP strategies. Dr. Kinsey earned a B.S. in Biomedical Engineering from Johns Hopkins University and completed his Ph.D. in Bioengineering at UC Berkeley and UCSF. In addition, he holds a certificate in Management of Technology from the Haas School of Business.

 

Paul chamberlin, md - chief medical officer

Dr. Chamberlin has significant experience in cardiovascular therapeutic research and clinical development. Prior to joining Ventrix in 2011, He was VP of Medical Development at Sequel Pharmaceuticals, and prior to that at NovaCardia, where he led research and clinical development of cardiac drugs for the treatment of heart failure and atrial fibrillation. Prior to NovaCardia, Dr. Chamberlin served in various positions at EPIX Pharmaceuticals, most recently as Executive Medical Director. He also worked in the Healthcare Practice of Arthur D. Little and the biotechnology division of Rhone-Poulenc-Rorer. Dr. Chamberlin earned a B.A. in Biology from the University of Pennsylvania and completed his M.D. at Boston University.

 

Brian Farmer - Business development

Mr. Farmer has 18 years of experience leading business development efforts in the health care industry. He was most recently VP of Corporate Development and Operations at Sequel Pharmaceuticals. Mr. Farmer was also responsible for corporate development at NovaCardia, acquired by Merck in 2007. Prior to NovaCardia, he was a Global Marketing Associate at Eli Lilly and worked in Marketing and Sales Operations for Prudential HealthCare. Mr. Farmer earned a B.S. from Trinity University and an M.B.A. from the University of Texas.

 

Jessica dequach, phd - research manager

Dr. DeQuach has expertise in research of biomaterial technology for regenerative medicine including tissue engineering scaffolds to treat ischemia in the brain, skeletal muscle, and heart. Dr. DeQuach earned her B.S. in Biomedical Engineering at Case Western Reserve University and completed her Ph.D. in Bioengineering at UCSD.

 

karen christman, phd - scientific co-founder

Dr. Christman co-founded Ventrix in 2009 and guided the initial scientific research to develop VentriGel from benchside to a translatable clinical therapy. Dr. Christman is a Professor in the Department of Bioengineering and a member of the Institute of Engineering in Medicine at UCSD. She has received numerous awards for her work on developing biomaterials for treating cardiovascular disease including the NIH Director’s New Innovator and Transformative Research Awards, the American Heart Association Innovative Sciences Award, and the Wallace H. Coulter Foundation Early Career Translational Research Award. She completed a NIH postdoctoral fellowship at UCLA in Polymer Chemistry. Dr. Christman earned a B.S. in Biomedical Engineering from Northwestern University and a Ph.D. in Bioengineering from UC Berkeley and UCSF.